Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company's new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Jun 22, 2026

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data

GlobeNewsWire • Jun 17, 2026

Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program

Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares for its Investor Day, where it will detail its plans for submitting a New Drug Application (NDA) for AXPAXLI.

Benzinga • Jun 17, 2026

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Seeking Alpha • Jun 18, 2026

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DNA technology to search and replace genetic mutations at their source.

The Motley Fool • Jun 15, 2026

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

GlobeNewsWire • Jun 4, 2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M.

GlobeNewsWire • Jun 2, 2026

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 5, 2026

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI's unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027 HELIOS-3 Phase 3 trial in diabetic retinopathy ongoing Ocular to host Investor Day on Wednesday, June 17, 2026, in New York City, including key program and regulatory updates Cash balance of $666.7 million as of March 31, 2026, with expected runway into 2028 BEDFORD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.

GlobeNewsWire • May 5, 2026